# To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

> **NCT01951846** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 61 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01951846
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2013-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951846, "To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01951846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*